Issued in 2024 and effective in 2026, the Quality Management System Regulation amends 21 CFR Part 820 to incorporate ISO 13485:2016 by reference, with additional FDA-specific requirements for records, labeling, and complaint reporting. The QMSR took effect on February 2, 2026. It retires most of the old QSR section numbers, adopts ISO 13485 terms such as 'medical device file', and keeps FDA-specific requirements on topics like complaint records, UDI and labeling controls. FDA also replaced its QSIT inspection approach with a new inspection process, and records from management reviews, internal audits and supplier audits are no longer exempt from FDA inspection.

Why it matters

QMSR aligns U.S. quality system expectations with international practice while retaining FDA-specific requirements around records access, labeling, unique device identification, complaint files, and servicing. Effective February 2, 2026, QMSR replaces the previous 21 CFR Part 820 QSR structure. Manufacturers must reconcile procedures, terminology (device master record vs medical device file), and records strategies before the effective date, and update supplier agreements and training programs to reflect the ISO 13485:2016 vocabulary.

Common pitfalls

•Assuming ISO 13485 conformance alone is sufficient under QMSR. FDA retains specific provisions for records access, labeling, UDI, complaint files, and servicing.
•Waiting until 2026 to start the transition. Auditors expect evidence of a planned, documented harmonization effort well before the effective date.
•Retiring QSR terminology (DMR/DHF/DHR) without a cross-reference matrix, which breaks traceability across legacy records.
•Ignoring supplier agreements. Many quality agreements reference 21 CFR Part 820 clauses that no longer exist under QMSR.

Sources

QMSR Final Rule (Federal Register) · Federal Register
FDA QMSR Final Rule Page · FDA
MDIC Case for Quality · MDIC

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.